HIF-1α inhibitors and mechanisms of action
| HIF-1α Inhibitor | Mechanism | Reference |
|---|---|---|
| Magnolol | Suppresses PI3K-Akt-mTOR pathway | Chen et al., 2013 |
| Sorafenib | Decreases phosphorylation of mTOR and its downstream effectors p70S6K and 4E-BP1 | Liu et al., 2012 |
| YC-1 | Suppresses the PI3K-Akt-mTOR-4E-BP pathway | Sun et al., 2007 |
| BEZ235 | Inhibits both PI3K and mTOR by interacting with their ATP-binding clefts | Karar et al., 2012 |
| Meformina | Inactivates mTOR by increasing the levels of REDD1 | Ben Sahra et al., 2011 |
| Deferasiroa | Inactivates mTOR by increasing the levels of REDD1 | Ohyashiki et al., 2009 |
| SP600125a | Inactivates mTOR by increasing the levels of REDD1 | Jin et al., 2009 |
| Topotecan | Prevents translation of HIF-1α mRNA | Rapisarda et al., 2004 |
| PX-478 | 1) Decreases HIF-1α mRNA levels; 2) prevents HIF-1α translation; and 3) prevents HIF-1α deubiquitination | Lee et al., 2011 |
↵a May actually increase HIF-1α levels.